SG80530A1 - Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen - Google Patents
Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogenInfo
- Publication number
- SG80530A1 SG80530A1 SG9603649A SG1996003649A SG80530A1 SG 80530 A1 SG80530 A1 SG 80530A1 SG 9603649 A SG9603649 A SG 9603649A SG 1996003649 A SG1996003649 A SG 1996003649A SG 80530 A1 SG80530 A1 SG 80530A1
- Authority
- SG
- Singapore
- Prior art keywords
- antiandrogen
- alpha
- treatment
- reductase inhibitor
- pharmaceutical combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67251191A | 1991-03-20 | 1991-03-20 | |
US84615392A | 1992-03-11 | 1992-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG80530A1 true SG80530A1 (en) | 2001-05-22 |
Family
ID=27100766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG9603649A SG80530A1 (en) | 1991-03-20 | 1992-03-19 | Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen |
Country Status (18)
Country | Link |
---|---|
US (2) | US5753641A (cs) |
EP (1) | EP0576603A1 (cs) |
JP (1) | JPH06506227A (cs) |
AU (1) | AU666846B2 (cs) |
BG (1) | BG61798B1 (cs) |
CA (1) | CA2104793C (cs) |
CZ (1) | CZ292712B6 (cs) |
HU (1) | HUT66273A (cs) |
IE (1) | IE920879A1 (cs) |
IL (1) | IL101243A (cs) |
NO (1) | NO305635B1 (cs) |
NZ (1) | NZ241979A (cs) |
RO (1) | RO113613B1 (cs) |
RU (1) | RU2125879C1 (cs) |
SG (1) | SG80530A1 (cs) |
SK (1) | SK284381B6 (cs) |
UA (1) | UA41305C2 (cs) |
WO (1) | WO1992016213A1 (cs) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0547687A1 (en) * | 1991-12-18 | 1993-06-23 | Merck & Co. Inc. | 17B-N-Substituted adamantyl/norbonanyl carbamoyl-4-aza-5a-and-rost-1-en-3-ones and androstan-3 ones |
WO1993019758A1 (en) * | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compositions and methods for treating benign prostatic hypertrophy |
NZ257993A (en) * | 1992-11-04 | 1997-05-26 | Sepracor Inc | Use of (+)-doxazosin and medicament containing the compound |
CA2158345A1 (en) * | 1993-03-15 | 1994-09-29 | Marvin L. Bayne | Cloned human alpha 1c adrenergic receptor |
TW408127B (en) * | 1993-09-17 | 2000-10-11 | Glaxo Inc | Androstenones |
TW369521B (en) * | 1993-09-17 | 1999-09-11 | Smithkline Beecham Corp | Androstenone derivative |
US5525608A (en) * | 1994-04-20 | 1996-06-11 | Merck & Co., Inc. | 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors |
US5817818A (en) * | 1994-09-16 | 1998-10-06 | Glaxo Wellcome Inc. | Androstenones |
US5541322A (en) * | 1994-10-14 | 1996-07-30 | Glaxo Wellcome Inc. | Synthesis of 6-azaandrostenones |
GB9603457D0 (cs) * | 1996-02-19 | 1996-04-17 | Merck & Co Inc | |
US6096763A (en) * | 1995-02-23 | 2000-08-01 | Merck & Co., Inc. | α1a adrenergic receptor antagonists |
US5952351A (en) * | 1995-02-23 | 1999-09-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US5670643A (en) * | 1995-03-16 | 1997-09-23 | Glaxo Wellcome Inc. | Method for preparing finasteride |
GB9506678D0 (en) * | 1995-03-31 | 1995-05-24 | Glaxo Inc | Substituted 6-azacholesten-3-ones |
USRE39056E1 (en) * | 1995-09-15 | 2006-04-04 | Merck & Co, Inc. | 4-Azasteroids for treatment of hyperandrogenic conditions |
US6177430B1 (en) | 1997-03-27 | 2001-01-23 | Pfizer Inc | Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia |
US5922722A (en) * | 1996-11-12 | 1999-07-13 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6376503B1 (en) | 1997-06-18 | 2002-04-23 | Merck & Co., Inc | Alpha 1a adrenergic receptor antagonists |
US6214832B1 (en) | 1997-06-18 | 2001-04-10 | Merck & Co., Inc. | Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists |
US6080760A (en) * | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
US6143750A (en) * | 1997-06-18 | 2000-11-07 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6037354A (en) * | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US6057350A (en) * | 1997-06-18 | 2000-05-02 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
US5998427A (en) * | 1998-05-14 | 1999-12-07 | Glaxo Wellcome Inc. | Androstenones |
AU5234899A (en) | 1998-07-30 | 2000-02-21 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
WO2000025782A1 (en) | 1998-10-29 | 2000-05-11 | Merck & Co., Inc. | Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists |
US6319932B1 (en) | 1998-11-10 | 2001-11-20 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1A adrenoceptor antagonists |
US6228870B1 (en) | 1998-11-10 | 2001-05-08 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
AU1345600A (en) | 1998-11-12 | 2000-06-05 | Merck & Co., Inc. | Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists |
US6358959B1 (en) | 1999-01-26 | 2002-03-19 | Merck & Co., Inc. | Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists |
US6313131B1 (en) | 1999-02-16 | 2001-11-06 | Upsher-Smith Laboratories, Inc. | Method of kidney treatment |
US6423719B1 (en) | 1999-02-16 | 2002-07-23 | Upsher-Smith Laboratories, Inc. | Method for treating benign prostate hyperplasia |
GB2355457A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355264A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355456A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355263A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists |
US6200573B1 (en) | 1999-12-03 | 2001-03-13 | Starcor Pharmaceuticals, Inc. | Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia |
AU2002322493A1 (en) * | 2001-07-10 | 2003-01-29 | Ams Research Corporation | Surgical kit for treating prostate tissue |
US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
US20040235808A1 (en) * | 2001-09-21 | 2004-11-25 | Jiabing Wang | Androstanes as androgen receptor modulators |
CN1646135A (zh) * | 2002-04-24 | 2005-07-27 | 贝林格尔英格海姆法玛两合公司 | 治疗良性前列腺增生或长期预防急性尿潴留的药物组合 |
BR0317287A (pt) * | 2002-12-23 | 2005-11-08 | Basf Ag | Composto, uso do mesmo, preparação e processo para tratamento de superfìcies metálicas, e, compósito |
EP1660184A4 (en) | 2003-06-30 | 2008-05-14 | Merck & Co Inc | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR |
CN1816370A (zh) * | 2003-06-30 | 2006-08-09 | 麦克公司 | 用作雄激素受体调节剂的17-乙酰氨基-4-氮杂甾族化合物衍生物 |
WO2005004807A2 (en) * | 2003-06-30 | 2005-01-20 | Merck & Co., Inc. | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
WO2005009949A2 (en) * | 2003-06-30 | 2005-02-03 | Merck & Co., Inc. | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
EP3510959B1 (en) | 2007-01-02 | 2021-03-03 | AquaBeam LLC | Minimally invasive devices for the treatment of prostate diseases |
US9232959B2 (en) | 2007-01-02 | 2016-01-12 | Aquabeam, Llc | Multi fluid tissue resection methods and devices |
MX2007003949A (es) * | 2007-04-02 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzima (-reductasa y un antagonista de los receptores 1 (-adrenergicos. |
US20080245375A1 (en) * | 2007-04-05 | 2008-10-09 | Medtronic Vascular, Inc. | Benign Prostatic Hyperplasia Treatments |
US20090076058A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched finasteride |
EP2259742B1 (en) | 2008-03-06 | 2020-01-01 | AquaBeam LLC | Tissue ablation and cautery with optical energy carried in fluid stream |
GR1006492B (el) * | 2008-05-29 | 2009-07-22 | Νικολαος Χρηστου Δημοφιλος | Συνεργατικη επαγωγη αποπτωσης προστατικου ιστου-προληψη καρκινου προστατου-νεα πρακτικη περιφερικου ανδρογονικου αποκλεισμου-κατασκευη συμπλοκου δισκιου |
WO2016037137A1 (en) | 2014-09-05 | 2016-03-10 | Procept Biorobotics Corporation | Physician controlled tissue resection integrated with treatment mapping of target organ images |
US9848904B2 (en) | 2009-03-06 | 2017-12-26 | Procept Biorobotics Corporation | Tissue resection and treatment with shedding pulses |
WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
BRPI1103204A2 (pt) * | 2011-06-03 | 2014-02-25 | Eurofarma Lab S A | Composição farmacêutica para o tratamento de hiperplasia prostática benigna |
CN104203078B (zh) | 2012-02-29 | 2018-04-20 | 普罗赛普特生物机器人公司 | 自动化图像引导的组织切除和处理 |
JP6403695B2 (ja) | 2013-02-14 | 2018-10-10 | プロセプト バイオロボティクス コーポレイション | アクアアブレーションアクアビーム眼科手術方法および装置 |
KR20160033220A (ko) | 2013-07-23 | 2016-03-25 | 알러간, 인코포레이티드 | 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물 |
MX2016001032A (es) * | 2013-07-23 | 2017-10-31 | Allergan Inc | Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa. |
BR112016005036A2 (pt) | 2013-09-06 | 2020-04-07 | Procept Biorobotics Corp | aparelho para ressecção de tecido guiada por imagem automatizada |
CN106572864B (zh) | 2014-06-30 | 2020-06-09 | 普罗赛普特生物机器人公司 | 流体射流组织切除和寒凝装置 |
CN104277089A (zh) * | 2014-09-30 | 2015-01-14 | 湖南科瑞生物科技有限公司 | 一种雄甾-17β-羧酸的制备方法 |
MX2017006655A (es) | 2014-11-20 | 2018-03-12 | Allergan Inc | Metodos y composiciones que comprenden desmopresina en combinacion con un antagonista del receptor alfa-adrenergico. |
US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
KR102680792B1 (ko) * | 2018-12-06 | 2024-07-03 | 경희대학교 산학협력단 | 신코닌을 유효성분으로 포함하는 전립선비대증의 예방 또는 치료용 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0155096A2 (en) * | 1984-02-27 | 1985-09-18 | Merck & Co. Inc. | 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors |
DE3607651A1 (de) * | 1986-03-06 | 1987-09-10 | Schering Ag | Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer |
EP0291245A2 (en) * | 1987-05-11 | 1988-11-17 | Ono Pharmaceutical Co., Ltd. | Benzoylaminophenoxybutanoic acid derivatives |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3238215A (en) * | 1963-10-17 | 1966-03-01 | Sterling Drug Inc | 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines |
GB1156973A (en) * | 1965-07-06 | 1969-07-02 | Quinazoline Derivatives | |
US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
US3980650A (en) * | 1972-05-05 | 1976-09-14 | N.V. Koninklijke Pharmaceutische Fabrieken V/H Brocades-Stheeman En Pharmacia | 4-Amino-pyrimidine derivatives |
JPS4966691A (cs) * | 1972-10-30 | 1974-06-27 | ||
US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
GB2007656B (en) * | 1977-11-05 | 1982-05-19 | Pfizer Ltd | Therapeutic agents |
US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
FR2421888A1 (fr) * | 1978-02-06 | 1979-11-02 | Synthelabo | Amides d'alkylene-diamines et leur application en therapeutique |
US4377584A (en) * | 1978-04-13 | 1983-03-22 | Merck & Co., Inc. | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors |
AU527030B2 (en) * | 1978-04-13 | 1983-02-10 | Merck & Co., Inc. | 4-aza-17-substituted-5a-androstan-3-ones |
US4220775A (en) * | 1979-03-15 | 1980-09-02 | Merck & Co., Inc. | Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors |
ATE67503T1 (de) * | 1984-02-27 | 1991-10-15 | Merck & Co Inc | 17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren. |
US4859681A (en) * | 1984-02-27 | 1989-08-22 | Merck & Co., Inc. | 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors |
US4760071A (en) * | 1984-02-27 | 1988-07-26 | Merck & Co., Inc. | 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors |
CA1261835A (en) * | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
US4888366A (en) * | 1984-10-24 | 1989-12-19 | Collagen Corporation | Inductive collagen-based bone repair preparations |
GB8505862D0 (en) * | 1985-03-07 | 1985-04-11 | Erba Farmitalia | Steroidic 5alpha-reductase inhibitors |
US4845104A (en) * | 1986-11-20 | 1989-07-04 | Merck & Co., Inc. | Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones |
US4888336A (en) * | 1987-01-28 | 1989-12-19 | Smithkline Beckman Corporation | Steroid 5-alpha-reductase inhibitors |
US4910226A (en) * | 1987-04-29 | 1990-03-20 | Smithkline Beckman Corporation | Steroid 5-alpha-reductase inhibitors |
JP2675418B2 (ja) * | 1988-05-25 | 1997-11-12 | スミスクライン・ベックマン・コーポレイション | 芳香族ステロイド5‐α‐レダクターゼ抑制剤 |
US5026882A (en) * | 1988-12-23 | 1991-06-25 | Smithkline Beecham Corporation | Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase |
US4970205A (en) * | 1988-12-23 | 1990-11-13 | Smithkline Beecham Corporation | Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase |
US4937237A (en) * | 1988-12-23 | 1990-06-26 | Smithkline Beckman Corporation | Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase |
US4882319A (en) * | 1988-12-23 | 1989-11-21 | Smithkline Beckman Corporation | Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase |
ZA901847B (en) * | 1989-03-10 | 1991-10-30 | Endorecherche Inc | Combination therapy for the treatment of estrogen sensitive diseases |
ES2189784T3 (es) * | 1989-07-07 | 2003-07-16 | Endorech Inc | Procedimiento para el tratamiento de enfermedades relacionadas con adrogenos. |
GR1001164B (el) * | 1989-07-07 | 1993-05-24 | Endorecherche Inc | Παραγωγα αρρενογονου ορμονης προς χρησιν εις την αναστολην δραστηριοτητος της στεροειδους ορμονης φυλου |
US5212176A (en) * | 1990-06-29 | 1993-05-18 | Abbott Laboratories | R(+)-terazosin |
US5399581A (en) * | 1990-12-26 | 1995-03-21 | Laragh; John H. | Method and compositions for treatment of sexual impotence |
WO1993019758A1 (en) * | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compositions and methods for treating benign prostatic hypertrophy |
-
1992
- 1992-03-16 NZ NZ241979A patent/NZ241979A/en not_active IP Right Cessation
- 1992-03-16 IL IL10124392A patent/IL101243A/en not_active IP Right Cessation
- 1992-03-19 IE IE087992A patent/IE920879A1/en not_active IP Right Cessation
- 1992-03-19 WO PCT/US1992/002258 patent/WO1992016213A1/en active IP Right Grant
- 1992-03-19 JP JP4509435A patent/JPH06506227A/ja active Pending
- 1992-03-19 RO RO93-01253A patent/RO113613B1/ro unknown
- 1992-03-19 CA CA002104793A patent/CA2104793C/en not_active Expired - Fee Related
- 1992-03-19 UA UA94061635A patent/UA41305C2/uk unknown
- 1992-03-19 AU AU17514/92A patent/AU666846B2/en not_active Ceased
- 1992-03-19 SG SG9603649A patent/SG80530A1/en unknown
- 1992-03-19 RU RU93055133A patent/RU2125879C1/ru not_active IP Right Cessation
- 1992-03-19 HU HU9302624A patent/HUT66273A/hu unknown
- 1992-03-19 EP EP92910266A patent/EP0576603A1/en not_active Withdrawn
- 1992-03-19 SK SK1006-93A patent/SK284381B6/sk unknown
- 1992-03-19 CZ CZ19931933A patent/CZ292712B6/cs not_active IP Right Cessation
-
1993
- 1993-09-17 NO NO933327A patent/NO305635B1/no unknown
- 1993-09-17 BG BG98113A patent/BG61798B1/bg unknown
-
1995
- 1995-04-25 US US08/428,595 patent/US5753641A/en not_active Expired - Lifetime
-
1998
- 1998-02-20 US US09/027,105 patent/US6046183A/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0155096A2 (en) * | 1984-02-27 | 1985-09-18 | Merck & Co. Inc. | 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors |
DE3607651A1 (de) * | 1986-03-06 | 1987-09-10 | Schering Ag | Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer |
EP0291245A2 (en) * | 1987-05-11 | 1988-11-17 | Ono Pharmaceutical Co., Ltd. | Benzoylaminophenoxybutanoic acid derivatives |
Also Published As
Publication number | Publication date |
---|---|
HUT66273A (en) | 1994-11-28 |
CA2104793C (en) | 2004-06-22 |
IE920879A1 (en) | 1992-09-23 |
UA41305C2 (uk) | 2001-09-17 |
EP0576603A1 (en) | 1994-01-05 |
BG98113A (bg) | 1994-06-30 |
HU9302624D0 (en) | 1993-12-28 |
BG61798B1 (bg) | 1998-06-30 |
CZ292712B6 (cs) | 2003-12-17 |
AU1751492A (en) | 1992-10-21 |
NZ241979A (en) | 1996-01-26 |
SK284381B6 (sk) | 2005-02-04 |
NO933327L (no) | 1993-11-17 |
RO113613B1 (ro) | 1998-09-30 |
US5753641A (en) | 1998-05-19 |
NO933327D0 (no) | 1993-09-17 |
AU666846B2 (en) | 1996-02-29 |
JPH06506227A (ja) | 1994-07-14 |
US6046183A (en) | 2000-04-04 |
RU2125879C1 (ru) | 1999-02-10 |
CZ193393A3 (en) | 1994-08-17 |
NO305635B1 (no) | 1999-07-05 |
SK100693A3 (en) | 1994-11-09 |
CA2104793A1 (en) | 1992-09-21 |
IL101243A0 (en) | 1992-11-15 |
WO1992016213A1 (en) | 1992-10-01 |
IL101243A (en) | 1999-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG80530A1 (en) | Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen | |
AU1893492A (en) | Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor | |
IL106431A0 (en) | Aminediol derivatives and pharmaceutical compositions containing the same | |
PH30794A (en) | Inhibition of phosphatidylinositol 3-kinase with worthmannin and analogs thereof. | |
FR2685869B1 (fr) | Compositions therapeutiques a base d'inhibiteurs mixtes de la no synthase et de la cyclooxygenase. | |
ZA933441B (en) | Inhibitors of testosterone 5 alpha-reductase activity | |
EG20279A (en) | New derivatives of 3 arylpyrazoles used as fungicides | |
HUP0102646A3 (en) | Phthalazine derivatives phosphodiesterase 4 inhibitors and pharmaceutical compositions containing the same | |
HK19496A (en) | Use of 1,2,2,3,3-penta-fluoropropane | |
AU1680292A (en) | Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen | |
HRP931012A2 (en) | Fungicidal 2-imidazoline-5-one and 2-imidazoline-5-thione derivatives | |
NO961226L (no) | Blandinger for forebyggelse og behandling av viralinduserte tumorer | |
EP0674707A4 (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF LEUCOMA. | |
AP9300591A0 (en) | "Fungicidal derivatives of 2-alkoxy-2-imidazolin-5-ones" | |
GB2267089B (en) | Cycloheptimidazole derivatives,method of manufacturing the same and therapeutic agents containing these compounds | |
EP0707640A4 (en) | (1 $ m (7) 3, 1 $ m (7) 4) - $ g (b) -GLUCANASE HAVING IMPROVED STABILITY | |
PL301653A1 (en) | Pharmaceutical agent for preventing or treating arteriosclerosis | |
EP0733365A3 (en) | Use of benzoquinolin-3-one for the treatment and prevention of prostate cancer | |
EP0653208A3 (en) | Substance P antagonists for the treatment or prevention of sunburn. | |
EP0644716A4 (en) | Medical uses of trioxolane and diperoxide compounds. | |
ZA927393B (en) | Regioselective synthesis of 1,5-diarylpyrazole anti-inflammatory agents | |
GB9317943D0 (en) | Treatment of laminitis | |
GB2280438B (en) | Carboxymethylidenecycloheptimidazole derivatives,method of manufacturing the same and therapeutic agents containing these compounds | |
PL301683A1 (en) | Hydroxamic acids, their derivatives and fungicide containing such compounds | |
GB9412413D0 (en) | Boiler treatment and novel compounds therefor |